🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 81 of 114

  1. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  2. Roflumilast 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  3. Roflumilast Cream

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  4. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  5. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  6. Roflumilast Foam

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 3 small molecule completed

    1 trial

  7. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Scalp Psoriasis

    phase 3 small molecule completed

    1 trial

  8. Romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  9. Ropeginterferon alfa-2b

    PharmaEssentia

    Primary Myelofibrosis

    phase 3 mab active

    1 trial

  10. Ropivacaine HCL

    Atrium Therapeutics

    Renal Carcinoma

    phase 3 small molecule active

    1 trial

  11. Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  12. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  13. Rosuvastatin 20mg

    AstraZeneca

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule completed

    1 trial

  14. Rosuvastatin Placebo, MK-0616 (Enlicitide chloride) Placebo, MK-0616, ROSUVASTATIN

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  15. Roux-en-Y anastomosis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  16. Roxadustat

    AstraZeneca

    Anemia

    phase 3 small molecule completed

    1 trial

  17. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  18. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  19. Rucaparib

    pharmaand GmbH

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  20. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare Pty Ltd

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  21. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  22. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial

  23. Ruxolitinib (INCB018424) cream, Ruxolitinib (INCB018424) cream, Vehicle (placebo) cream

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  24. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  25. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  26. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  27. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  28. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  29. S-1 therapy

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  30. S-217622

    Shionogi B.V.

    SARS-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  31. S-268019-b

    Shionogi B.V.

    SARS-CoV-2

    phase 3 small molecule completed

    1 trial

  32. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Super-refractory Status Epilepticus

    phase 3 small molecule completed

    2 trials

  33. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

  34. SALBUTAMOL , Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  35. SALINE, Fazirsiran

    Takeda

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    phase 3 small molecule active

    1 trial

  36. SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND

    Arcus Biosciences

    Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  37. SAMYR 400 mg compresse gastroresistenti, Samyr placebo (same excipient as SAMYR)

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

  38. SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs

    phase 3 small molecule active

    1 trial

  39. SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    2 trials

  40. SAR439774

    Genzyme Europe B.V.

    Hemophilia

    phase 3 small molecule active

    1 trial

  41. SAR439774, SAR439774

    Sanofi-aventis Healthcare Pty Ltd

    Hemophilia

    phase 3 small molecule active

    1 trial

  42. SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  43. SARS-CoV-2 Vaccine (Vero Cell), Inactivated

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 3 mab completed

    1 trial

  44. SARS-CoV-2 inactivated vaccine

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  45. SARS-CoV-2 mRNA Vaccine

    Biotech Pharmaceutical Co.,

    COVID-19

    phase 3 mab active

    1 trial

  46. SARS-CoV-2 vaccine (inactivated)

    Sinovac Research and Development Co.,

    SARS-CoV2 Infection

    phase 3 mab completed

    1 trial

  47. SAU

    BRIGHT MINDS BIOSCIENCES INC.

    Signs and Symptoms

    phase 3 other completed

    1 trial

  48. SB-497115-GR 12.5mg

    GlaxoSmithKline

    Chronic Idiopathic Thrombocytopenic Purpura

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.